Progress and Understandings in the Pharmacological Repositioning Scenario

Abstract

In order to present an overview of pharmacological repositioning in terms of clinical applicability, a narrative review was applied, based on the PCC strategy. The search was carried out in February 2022, highlighting the concepts on the subject, not requiring the opinion of a committee for its development. Numerous drugs were randomly repositioned. It is noteworthy that during clinical trials, unexpected side effects made its reuse possible. The antiplatelet effect of aspirin is already elucidated, however, research reveals potential in oncology. Therefore, there is a need to explore the biochemistry and the interaction with organic and pathological targets, visualizing the applicability of known drugs in solving urgent problems.